JP2023539056A - Ｔ細胞を製造する組成物および方法 - Google Patents

Ｔ細胞を製造する組成物および方法 Download PDF

Info

Publication number
JP2023539056A
JP2023539056A JP2023509799A JP2023509799A JP2023539056A JP 2023539056 A JP2023539056 A JP 2023539056A JP 2023509799 A JP2023509799 A JP 2023509799A JP 2023509799 A JP2023509799 A JP 2023509799A JP 2023539056 A JP2023539056 A JP 2023539056A
Authority
JP
Japan
Prior art keywords
cells
population
antigen
culture medium
peptide antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509799A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022036137A5 (https=
JP2023539056A5 (https=
Inventor
ヴィクラム ジュネジャ，
ジャレッド ディーツェ，
ブランドン コン，
ジェウォン チェ，
Original Assignee
ビオンテック ユーエス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビオンテック ユーエス インコーポレイテッド filed Critical ビオンテック ユーエス インコーポレイテッド
Publication of JP2023539056A publication Critical patent/JP2023539056A/ja
Publication of JPWO2022036137A5 publication Critical patent/JPWO2022036137A5/ja
Publication of JP2023539056A5 publication Critical patent/JP2023539056A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Moulding By Coating Moulds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Casting Or Compression Moulding Of Plastics Or The Like (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023509799A 2020-08-13 2021-08-12 Ｔ細胞を製造する組成物および方法 Pending JP2023539056A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063065327P 2020-08-13 2020-08-13
US63/065,327 2020-08-13
PCT/US2021/045800 WO2022036137A1 (en) 2020-08-13 2021-08-12 T cell manufacturing compositions and methods

Publications (3)

Publication Number Publication Date
JP2023539056A true JP2023539056A (ja) 2023-09-13
JPWO2022036137A5 JPWO2022036137A5 (https=) 2024-08-21
JP2023539056A5 JP2023539056A5 (https=) 2024-08-21

Family

ID=80248187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509799A Pending JP2023539056A (ja) 2020-08-13 2021-08-12 Ｔ細胞を製造する組成物および方法

Country Status (14)

Country Link
US (1) US20230374455A1 (https=)
EP (1) EP4196135A4 (https=)
JP (1) JP2023539056A (https=)
KR (1) KR20230074719A (https=)
CN (1) CN116710551A (https=)
AU (1) AU2021325081A1 (https=)
BR (1) BR112023002733A2 (https=)
CA (1) CA3189285A1 (https=)
CL (1) CL2023000437A1 (https=)
CO (1) CO2023002953A2 (https=)
CU (1) CU20230011A7 (https=)
IL (1) IL300564A (https=)
MX (1) MX2023001815A (https=)
WO (1) WO2022036137A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
WO2023159088A1 (en) * 2022-02-15 2023-08-24 Marker Therapeutics, Inc. Compositions and methods for antigen-specific t cell expansion
CA3254900A1 (en) * 2022-03-30 2023-10-05 Mdx Management Llc COMPOSITIONS AND METHODS FOR ACTIVATING IMMUNE CELLS
CN121548636A (zh) * 2023-06-19 2026-02-17 北京沙砾生物医药股份有限公司 一种肿瘤特异性细胞的富集方法和应用
WO2025245492A1 (en) * 2024-05-24 2025-11-27 Biontech Us Inc. Compositions and methods for t cell manufacturing and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094642A1 (en) * 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
WO2020047449A2 (en) * 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094642A1 (en) * 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WOLFL, M. ET AL.: "Activation-induced expression of CD137 permits detection, isolation, and expansion of the full reper", BLOOD, vol. 110, no. 1, JPN6025041206, 2007, pages 201 - 210, ISSN: 0005831932 *

Also Published As

Publication number Publication date
BR112023002733A2 (pt) 2023-05-02
EP4196135A1 (en) 2023-06-21
EP4196135A4 (en) 2024-08-21
CN116710551A (zh) 2023-09-05
MX2023001815A (es) 2023-04-11
CL2023000437A1 (es) 2023-07-28
KR20230074719A (ko) 2023-05-31
CA3189285A1 (en) 2022-02-17
IL300564A (en) 2023-04-01
CO2023002953A2 (es) 2023-05-19
CU20230011A7 (es) 2023-12-07
AU2021325081A1 (en) 2023-04-13
WO2022036137A1 (en) 2022-02-17
US20230374455A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
JP7420856B2 (ja) Ｔ細胞を製造する組成物及び方法
KR102756321B1 (ko) T 세포 제조 조성물 및 방법
JP2023539056A (ja) Ｔ細胞を製造する組成物および方法
CA3234993A1 (en) T cell manufacturing compositions and methods
RU2793344C2 (ru) Композиции и способы для производства т-клеток
WO2025227066A2 (en) Ras vaccine compositions and methods of use
WO2025179050A2 (en) Vaccine compositions and methods of use
CN118574629A (zh) T细胞制备组合物和方法
HK40115457A (zh) T细胞制备组合物和方法
HK40071072A (en) T cell manufacturing compositions and methods
HK40071072B (zh) T细胞制备组合物和方法
HK40039283A (en) T cell manufacturing compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260402